Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(6):748–753. doi: 10.1054/bjoc.2000.1660

Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma

M H Kulke 1, R D Odze 2, K S Thakore 1, G Thomas 1, H Wang 3, M Loda 1,2, C Eng 4
PMCID: PMC2363812  PMID: 11259087

Abstract

PTEN is a putative tumour suppressor gene located on chromosome band 10q23. Mutations in PTEN have been identified in numerous human malignancies, including cancers of the brain, endometrium, ovary, and prostate. In this study, we screened 80 Barrett's oesophagus-associated adenocarcinomas (BOAd) for loss of heterozygosity (LOH) at 10q23, using the microsatellite markers D10S541, D10S219, and D10S551. Tumours demonstrating LOH were then screened for the presence or absence of PTEN mutations. LOH at one or more loci was identified in 17/80 (21%) cases. In none of these cases did we detect mutations in PTEN. The presence of LOH did not correlate with patient age, tumour stage, degree of differentiation, presence of perineural or vascular invasion, or overall survival. We conclude that LOH at chromosome 10q23 is uncommon in BOAd, is not associated with mutations in the PTEN tumour suppressor gene, and does not correlate with the clinical or pathologic features of these tumours. It is possible that PTEN is inactivated through other mechanisms in BOAd. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: PTEN, Barrett's oesophagus, oesophageal adenocarcinoma, 10q23

Full Text

The Full Text of this article is available as a PDF (124.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alimov A., Li C., Gizatullin R., Fredriksson V., Sundelin B., Klein G., Zabarovsky E., Bergerheim U. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 1999 Sep-Oct;19(5B):3841–3846. [PubMed] [Google Scholar]
  2. Aveyard J. S., Skilleter A., Habuchi T., Knowles M. A. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer. 1999 May;80(5-6):904–908. doi: 10.1038/sj.bjc.6690439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blot W. J., Devesa S. S., Kneller R. W., Fraumeni J. F., Jr Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287–1289. [PubMed] [Google Scholar]
  4. Bose S., Wang S. I., Terry M. B., Hibshoosh H., Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene. 1998 Jul 9;17(1):123–127. doi: 10.1038/sj.onc.1201940. [DOI] [PubMed] [Google Scholar]
  5. Boström J., Cobbers J. M., Wolter M., Tabatabai G., Weber R. G., Lichter P., Collins V. P., Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998 Jan 1;58(1):29–33. [PubMed] [Google Scholar]
  6. Boynton R. F., Blount P. L., Yin J., Brown V. L., Huang Y., Tong Y., McDaniel T., Newkirk C., Resau J. H., Raskind W. H. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3385–3388. doi: 10.1073/pnas.89.8.3385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Butler M. P., Wang S. I., Chaganti R. S., Parsons R., Dalla-Favera R. Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer. 1999 Apr;24(4):322–327. [PubMed] [Google Scholar]
  8. Cairns P., Evron E., Okami K., Halachmi N., Esteller M., Herman J. G., Bose S., Wang S. I., Parsons R., Sidransky D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998 Jun 18;16(24):3215–3218. doi: 10.1038/sj.onc.1201855. [DOI] [PubMed] [Google Scholar]
  9. Chen S. T., Yu S. Y., Tsai M., Yeh K. T., Wang J. C., Kao M. C., Shih M. C., Chang J. G. Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat. 1999 May;55(1):85–89. doi: 10.1023/a:1006142919428. [DOI] [PubMed] [Google Scholar]
  10. Chiariello E., Roz L., Albarosa R., Magnani I., Finocchiaro G. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene. 1998 Jan 29;16(4):541–545. doi: 10.1038/sj.onc.1201689. [DOI] [PubMed] [Google Scholar]
  11. Dahia P. L., Aguiar R. C., Alberta J., Kum J. B., Caron S., Sill H., Marsh D. J., Ritz J., Freedman A., Stiles C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet. 1999 Feb;8(2):185–193. doi: 10.1093/hmg/8.2.185. [DOI] [PubMed] [Google Scholar]
  12. Dahia P. L., Marsh D. J., Zheng Z., Zedenius J., Komminoth P., Frisk T., Wallin G., Parsons R., Longy M., Larsson C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997 Nov 1;57(21):4710–4713. [PubMed] [Google Scholar]
  13. Davies M. P., Gibbs F. E., Halliwell N., Joyce K. A., Roebuck M. M., Rossi M. L., Salisbury J., Sibson D. R., Tacconi L., Walker C. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer. 1999 Mar;79(9-10):1542–1548. doi: 10.1038/sj.bjc.6690246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dolan K., Garde J., Gosney J., Sissons M., Wright T., Kingsnorth A. N., Walker S. J., Sutton R., Meltzer S. J., Field J. K. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer. 1998 Oct;78(7):950–957. doi: 10.1038/bjc.1998.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dong J. T., Sipe T. W., Hyytinen E. R., Li C. L., Heise C., McClintock D. E., Grant C. D., Chung L. W., Frierson H. F., Jr PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene. 1998 Oct 15;17(15):1979–1982. doi: 10.1038/sj.onc.1202119. [DOI] [PubMed] [Google Scholar]
  16. Duerr E. M., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D. N., Schramm J., Wiestler O. D., Parsons R., Eng C. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998 Apr 30;16(17):2259–2264. doi: 10.1038/sj.onc.1201756. [DOI] [PubMed] [Google Scholar]
  17. Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15;57(16):3381–3385. [PubMed] [Google Scholar]
  18. Feilotter H. E., Coulon V., McVeigh J. L., Boag A. H., Dorion-Bonnet F., Duboué B., Latham W. C., Eng C., Mulligan L. M., Longy M. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer. 1999 Feb;79(5-6):718–723. doi: 10.1038/sj.bjc.6690115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Feilotter H. E., Nagai M. A., Boag A. H., Eng C., Mulligan L. M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene. 1998 Apr 2;16(13):1743–1748. doi: 10.1038/sj.onc.1200205. [DOI] [PubMed] [Google Scholar]
  20. Fléjou J. F., Paraf F., Potet F., Muzeau F., Fékété F., Hénin D. p53 protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance. Histopathology. 1994 May;24(5):487–489. doi: 10.1111/j.1365-2559.1994.tb00561.x. [DOI] [PubMed] [Google Scholar]
  21. Freihoff D., Kempe A., Beste B., Wappenschmidt B., Kreyer E., Hayashi Y., Meindl A., Krebs D., Wiestler O. D., von Deimling A. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 1999 Feb;79(5-6):754–758. doi: 10.1038/sj.bjc.6690121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Garcia J. M., Silva J. M., Dominguez G., Gonzalez R., Navarro A., Carretero L., Provencio M., España P., Bonilla F. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat. 1999 Oct;57(3):237–243. doi: 10.1023/a:1006273516976. [DOI] [PubMed] [Google Scholar]
  23. Gasparotto D., Vukosavljevic T., Piccinin S., Barzan L., Sulfaro S., Armellin M., Boiocchi M., Maestro R. Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer. 1999 Aug 20;84(4):432–436. doi: 10.1002/(sici)1097-0215(19990820)84:4<432::aid-ijc18>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  24. Gimm O., Perren A., Weng L. P., Marsh D. J., Yeh J. J., Ziebold U., Gil E., Hinze R., Delbridge L., Lees J. A. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000 May;156(5):1693–1700. doi: 10.1016/s0002-9440(10)65040-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gleeson C. M., Sloan J. M., McGuigan J. A., Ritchie A. J., Russell S. E. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res. 1995 Aug 1;55(15):3406–3411. [PubMed] [Google Scholar]
  26. González M. V., Artímez M. L., Rodrigo L., López-Larrea C., Menéndez M. J., Alvarez V., Pérez R., Fresno M. F., Pérez M. J., Sampedro A. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol. 1997 Mar;50(3):212–217. doi: 10.1136/jcp.50.3.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gray I. C., Stewart L. M., Phillips S. M., Hamilton J. A., Gray N. E., Watson G. J., Spurr N. K., Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer. 1998 Nov;78(10):1296–1300. doi: 10.1038/bjc.1998.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Grønbaek K., Zeuthen J., Guldberg P., Ralfkiaer E., Hou-Jensen K. Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood. 1998 Jun 1;91(11):4388–4390. [PubMed] [Google Scholar]
  29. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  30. Hamelin R., Fléjou J. F., Muzeau F., Potet F., Laurent-Puig P., Fékété F., Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology. 1994 Oct;107(4):1012–1018. doi: 10.1016/0016-5085(94)90225-9. [DOI] [PubMed] [Google Scholar]
  31. Hammoud Z. T., Kaleem Z., Cooper J. D., Sundaresan R. S., Patterson G. A., Goodfellow P. J. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res. 1996 Oct 1;56(19):4499–4502. [PubMed] [Google Scholar]
  32. Huang Y., Boynton R. F., Blount P. L., Silverstein R. J., Yin J., Tong Y., McDaniel T. K., Newkirk C., Resau J. H., Sridhara R. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992 Dec 1;52(23):6525–6530. [PubMed] [Google Scholar]
  33. Kohno T., Takahashi M., Manda R., Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer. 1998 Jun;22(2):152–156. doi: 10.1002/(sici)1098-2264(199806)22:2<152::aid-gcc10>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  34. Kong D., Suzuki A., Zou T. T., Sakurada A., Kemp L. W., Wakatsuki S., Yokoyama T., Yamakawa H., Furukawa T., Sato M. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143–144. doi: 10.1038/ng1097-143. [DOI] [PubMed] [Google Scholar]
  35. Kurose K., Zhou X. P., Araki T., Eng C. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Genes Chromosomes Cancer. 2000 Oct;29(2):166–172. [PubMed] [Google Scholar]
  36. Lagergren J., Bergström R., Lindgren A., Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825–831. doi: 10.1056/NEJM199903183401101. [DOI] [PubMed] [Google Scholar]
  37. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  38. Liggett W. H., Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998 Mar;16(3):1197–1206. doi: 10.1200/JCO.1998.16.3.1197. [DOI] [PubMed] [Google Scholar]
  39. Liu W., James C. D., Frederick L., Alderete B. E., Jenkins R. B. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997 Dec 1;57(23):5254–5257. [PubMed] [Google Scholar]
  40. Marsh D. J., Dahia P. L., Caron S., Kum J. B., Frayling I. M., Tomlinson I. P., Hughes K. S., Eeles R. A., Hodgson S. V., Murday V. A. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998 Nov;35(11):881–885. doi: 10.1136/jmg.35.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Marsh D. J., Dahia P. L., Zheng Z., Liaw D., Parsons R., Gorlin R. J., Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997 Aug;16(4):333–334. doi: 10.1038/ng0897-333. [DOI] [PubMed] [Google Scholar]
  42. Marsh D. J., Kum J. B., Lunetta K. L., Bennett M. J., Gorlin R. J., Ahmed S. F., Bodurtha J., Crowe C., Curtis M. A., Dasouki M. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999 Aug;8(8):1461–1472. doi: 10.1093/hmg/8.8.1461. [DOI] [PubMed] [Google Scholar]
  43. Marsh D. J., Roth S., Lunetta K. L., Hemminki A., Dahia P. L., Sistonen P., Zheng Z., Caron S., van Orsouw N. J., Bodmer W. F. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res. 1997 Nov 15;57(22):5017–5021. [PubMed] [Google Scholar]
  44. McMenamin M. E., Soung P., Perera S., Kaplan I., Loda M., Sellers W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999 Sep 1;59(17):4291–4296. [PubMed] [Google Scholar]
  45. Mutter G. L., Lin M. C., Fitzgerald J. T., Kum J. B., Baak J. P., Lees J. A., Weng L. P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924–930. doi: 10.1093/jnci/92.11.924. [DOI] [PubMed] [Google Scholar]
  46. Muzeau F., Fléjou J. F., Thomas G., Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer. 1997 Jul 3;72(1):27–30. doi: 10.1002/(sici)1097-0215(19970703)72:1<27::aid-ijc3>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  47. Myers M. P., Stolarov J. P., Eng C., Li J., Wang S. I., Wigler M. H., Parsons R., Tonks N. K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052–9057. doi: 10.1073/pnas.94.17.9052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Nakahara Y., Nagai H., Kinoshita T., Uchida T., Hatano S., Murate T., Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia. 1998 Aug;12(8):1277–1280. doi: 10.1038/sj.leu.2401099. [DOI] [PubMed] [Google Scholar]
  49. Neshat K., Sanchez C. A., Galipeau P. C., Blount P. L., Levine D. S., Joslyn G., Reid B. J. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology. 1994 Jun;106(6):1589–1595. doi: 10.1016/0016-5085(94)90415-4. [DOI] [PubMed] [Google Scholar]
  50. Obata K., Morland S. J., Watson R. H., Hitchcock A., Chenevix-Trench G., Thomas E. J., Campbell I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998 May 15;58(10):2095–2097. [PubMed] [Google Scholar]
  51. Okami K., Wu L., Riggins G., Cairns P., Goggins M., Evron E., Halachmi N., Ahrendt S. A., Reed A. L., Hilgers W. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res. 1998 Feb 1;58(3):509–511. [PubMed] [Google Scholar]
  52. Pesche S., Latil A., Muzeau F., Cussenot O., Fournier G., Longy M., Eng C., Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene. 1998 Jun 4;16(22):2879–2883. doi: 10.1038/sj.onc.1202081. [DOI] [PubMed] [Google Scholar]
  53. Rasheed B. K., Stenzel T. T., McLendon R. E., Parsons R., Friedman A. H., Friedman H. S., Bigner D. D., Bigner S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997 Oct 1;57(19):4187–4190. [PubMed] [Google Scholar]
  54. Risinger J. I., Hayes A. K., Berchuck A., Barrett J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736–4738. [PubMed] [Google Scholar]
  55. Saito M., Okamoto A., Kohno T., Takakura S., Shinozaki H., Isonishi S., Yasuhara T., Yoshimura T., Ohtake Y., Ochiai K. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000 Jan 15;85(2):160–165. [PubMed] [Google Scholar]
  56. Sakai A., Thieblemont C., Wellmann A., Jaffe E. S., Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 1998 Nov 1;92(9):3410–3415. [PubMed] [Google Scholar]
  57. Schneider P. M., Casson A. G., Levin B., Garewal H. S., Hoelscher A. H., Becker K., Dittler H. J., Cleary K. R., Troster M., Siewert J. R. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg. 1996 Feb;111(2):323–333. doi: 10.1016/s0022-5223(96)70441-5. [DOI] [PubMed] [Google Scholar]
  58. Shao X., Tandon R., Samara G., Kanki H., Yano H., Close L. G., Parsons R., Sato T. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer. 1998 Aug 31;77(5):684–688. doi: 10.1002/(sici)1097-0215(19980831)77:5<684::aid-ijc4>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  59. Simpkins S. B., Peiffer-Schneider S., Mutch D. G., Gersell D., Goodfellow P. J. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol. 1998 Dec;71(3):391–395. doi: 10.1006/gyno.1998.5208. [DOI] [PubMed] [Google Scholar]
  60. Singh B., Ittmann M. M., Krolewski J. J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer. 1998 Feb;21(2):166–171. [PubMed] [Google Scholar]
  61. Singh S. P., Lipman J., Goldman H., Ellis F. H., Jr, Aizenman L., Cangi M. G., Signoretti S., Chiaur D. S., Pagano M., Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998 Apr 15;58(8):1730–1735. [PubMed] [Google Scholar]
  62. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  63. Suzuki H., Freije D., Nusskern D. R., Okami K., Cairns P., Sidransky D., Isaacs W. B., Bova G. S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998 Jan 15;58(2):204–209. [PubMed] [Google Scholar]
  64. Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997 Apr 1;57(7):1259–1263. [PubMed] [Google Scholar]
  65. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935–3940. [PubMed] [Google Scholar]
  66. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  67. Tsao H., Zhang X., Benoit E., Haluska F. G. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998 Jul 2;16(26):3397–3402. doi: 10.1038/sj.onc.1201881. [DOI] [PubMed] [Google Scholar]
  68. Vijeyasingam R., Darnton S. J., Jenner K., Allen C. A., Billingham C., Matthews H. R. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg. 1994 Nov;81(11):1623–1626. doi: 10.1002/bjs.1800811120. [DOI] [PubMed] [Google Scholar]
  69. Wang S. I., Puc J., Li J., Bruce J. N., Cairns P., Sidransky D., Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997 Oct 1;57(19):4183–4186. [PubMed] [Google Scholar]
  70. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246–5250. doi: 10.1073/pnas.95.9.5246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Yaginuma Y., Yamashita T., Ishiya T., Morizaki A., Katoh Y., Takahashi T., Hayashi H., Ishikawa M. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog. 2000 Feb;27(2):110–116. doi: 10.1002/(sici)1098-2744(200002)27:2<110::aid-mc6>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  72. Yang R. M., Naitoh J., Murphy M., Wang H. J., Phillipson J., deKernion J. B., Loda M., Reiter R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998 Mar;159(3):941–945. [PubMed] [Google Scholar]
  73. Yokomizo A., Tindall D. J., Drabkin H., Gemmill R., Franklin W., Yang P., Sugio K., Smith D. I., Liu W. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 1998 Jul 30;17(4):475–479. doi: 10.1038/sj.onc.1201956. [DOI] [PubMed] [Google Scholar]
  74. Zhou X. P., Gimm O., Hampel H., Niemann T., Walker M. J., Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000 Oct;157(4):1123–1128. doi: 10.1016/S0002-9440(10)64627-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Zhou X. P., Li Y. J., Hoang-Xuan K., Laurent-Puig P., Mokhtari K., Longy M., Sanson M., Delattre J. Y., Thomas G., Hamelin R. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer. 1999 Apr 20;84(2):150–154. doi: 10.1002/(sici)1097-0215(19990420)84:2<150::aid-ijc10>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  76. Zhou X., Tarmin L., Yin J., Jiang H. Y., Suzuki H., Rhyu M. G., Abraham J. M., Meltzer S. J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene. 1994 Dec;9(12):3737–3741. [PubMed] [Google Scholar]
  77. Zhuang Z., Vortmeyer A. O., Mark E. J., Odze R., Emmert-Buck M. R., Merino M. J., Moon H., Liotta L. A., Duray P. H. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res. 1996 May 1;56(9):1961–1964. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES